Drug Profile
Research programme: respiratory disease-associated proteins - Bayer/Celltech Group
Latest Information Update: 09 Oct 2006
Price :
$50
*
At a glance
- Originator Bayer; UCB
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Asthma; Chronic obstructive pulmonary disease; Respiratory tract disorders
Most Recent Events
- 09 Oct 2006 Discontinued - Preclinical for Asthma in United Kingdom (unspecified route)
- 09 Oct 2006 Discontinued - Preclinical for Chronic obstructive pulmonary disease in United Kingdom (unspecified route)
- 09 Oct 2006 Discontinued - Preclinical for Respiratory tract disorders in United Kingdom (unspecified route)